NEOsphere Biotechnologies GmbH

NEOsphere Biotechnologies integrates world-class mass spectrometry with expert data analysis to systematically build comprehensive pipelines of novel degrader targets. We support our partners' targeted protein degradation (TPD) drug discovery programs across all stages. Our deep proteomic screening platform, which is target- and E3 ligase-agnostic, enables unbiased, high-throughput screening of entire degrader libraries. With unparalleled proteome coverage, sensitivity, precision, and rapid turnaround, we unlock the previously undruggable target space. Our platform characterizes all degrader types, identifying molecules that engage new E3 ligases and emerging TPD mechanisms. We confirm potential degrader targets and modifications through global ubiquitinomics, achieving unprecedented coverage of > 50,000 ubiquitination sites. Our proprietary data analysis suite is designed for interactive and user-friendly exploration of large proteomics datasets, enabling informed decision-making, SAR optimization, target identification, and library expansion.